{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T11:22:26Z","timestamp":1774005746913,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.leukres.2026.108183","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:53:47Z","timestamp":1770191627000},"page":"108183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Favorable outcomes with fludarabine, melphalan, and total-body irradiation 8\u201312Gy as an intensified conditioning regimen for adult allogeneic HCT"],"prefix":"10.1016","volume":"162","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2357-685X","authenticated-orcid":false,"given":"Tomoyo","family":"Kubo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otoya","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Taya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyosuke","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosei","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Kaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Ishiwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Asano-Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Wake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2026.108183_bib1","doi-asserted-by":"crossref","first-page":"620.e1","DOI":"10.1016\/j.jtct.2021.03.026","article-title":"Impact of total body irradiation-based myeloablative conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: systematic review and meta-analysis","volume":"27","author":"Khimani","year":"2021","journal-title":"Transplant. Cell Ther."},{"issue":"25","key":"10.1016\/j.leukres.2026.108183_bib2","first-page":"06389","article-title":"Total-body irradiation-based versus chemotherapy alone as myeloablative conditioning regimen prior to hematopoietic allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia: a multi-institutional study from the SFGM-TC","volume":"S0360-3016","author":"Belkacemi","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.leukres.2026.108183_bib3","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/s41409-023-01966-w","article-title":"Total body irradiation versus busulfan-based intermediate-intensity conditioning for stem cell transplantation in ALL patients >45 years","volume":"58","author":"Hirschb\u00fchl","year":"2023","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.leukres.2026.108183_bib4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/ajh.23109","article-title":"Safety and efficacy of total body irradiation, cyclophosphamide, and cytarabine as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia","volume":"87","author":"Mori","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108183_bib5","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41409-023-01917-5","article-title":"Fludarabine or cyclophosphamide in combination with total body irradiation as myeloablative conditioning prior to allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia","volume":"58","author":"Giebel","year":"2023","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.leukres.2026.108183_bib6","doi-asserted-by":"crossref","first-page":"665.e1","DOI":"10.1016\/j.jtct.2021.04.029","article-title":"Outcomes of fludarabine, melphalan, and total body irradiation as a reduced-intensity conditioning regimen","volume":"27","author":"Modi","year":"2021","journal-title":"Transplant. Cell Ther."},{"key":"10.1016\/j.leukres.2026.108183_bib7","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-03-0754","article-title":"Successful engraftment after reduced-intensity umbilical cord blood transplantation","volume":"10","author":"Miyakoshi","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2026.108183_bib8","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the disease risk index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108183_bib9","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/TP.0b013e318223d7ac","article-title":"Mycophenolate and tacrolimus for graft-versus-host disease prophylaxis after cord blood transplantation","volume":"92","author":"Uchida","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.leukres.2026.108183_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/01.TP.0000163289.20406.86","article-title":"Early immune reaction after reduced-intensity cord-blood transplantation","volume":"80","author":"Kishi","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.leukres.2026.108183_bib11","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.leukres.2026.108183_bib12","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.bbmt.2008.03.003","article-title":"Umbilical cord blood transplantation after reduced-intensity conditioning","volume":"14","author":"Uchida","year":"2008","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.leukres.2026.108183_bib13","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1038\/s41409-021-01313-x","article-title":"Umbilical cord blood transplants facilitated by the French cord blood banks network","volume":"56","author":"Rafii","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.leukres.2026.108183_bib14","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.bbmt.2019.11.001","article-title":"Impact of HLA allele mismatch in single cord blood transplantation","volume":"26","author":"Yokoyama","year":"2020","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.leukres.2026.108183_bib15","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1182\/bloodadvances.2019001266","article-title":"Reduced-intensity conditioning using melphalan- vs busulfan-based regimens for AML","volume":"4","author":"Zhou","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2026.108183_bib16","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/cncr.29163","article-title":"Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan","volume":"121","author":"Baron","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2026.108183_bib17","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/jamaoncol.2024.0985","article-title":"Measurable residual FLT3-ITD before allogeneic transplant for AML","volume":"10","author":"Dillon","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.leukres.2026.108183_bib18","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood-2019-130550","article-title":"Pre-engraftment immune reactions have unique graft-versus-leukemia effects","volume":"134","author":"Yamamoto","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108183_bib19","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","article-title":"Redefining transplant conditioning intensity in AML","volume":"55","author":"Spyridonidis","year":"2020","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.leukres.2026.108183_bib20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood-2015-04-642652","article-title":"High-dose cytarabine added to CY\/TBI in cord blood transplantation","volume":"126","author":"Arai","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108183_bib21","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s12185-015-1836-7","article-title":"Cytarabine or thiotepa added to CY\/TBI for acute leukemia","volume":"102","author":"Tachibana","year":"2015","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108183_bib22","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.bbmt.2016.06.017","article-title":"Reduced-toxicity myeloablative conditioning using busulfan, fludarabine, and melphalan for cord blood transplantation","volume":"22","author":"Yamamoto","year":"2016","journal-title":"Biol. Blood Marrow Transpl."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T09:19:24Z","timestamp":1773998364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626000275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":22,"alternative-id":["S0145212626000275"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108183","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Favorable outcomes with fludarabine, melphalan, and total-body irradiation 8\u201312Gy as an intensified conditioning regimen for adult allogeneic HCT","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108183","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108183"}}